Skip to content

Net Income at other companies

Intuitive Surgical logo
Intuitive SurgicalISRG
$821.5M+17.6%
Medtronic logo
MedtronicMDT
$1.24B+17.8%
AngioDynamics logo
AngioDynamicsANGO
-$8.08M-83.4%
ITG
Integer HoldingsITGR
$16.51M+173%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$41M+36.0%
Stereotaxis logo
StereotaxisSTXS
-$5.86M-0.7%

Other financials

Income statement

See full
Revenue$105.0K
Gross profit$2.0K
Operating income-$4.3M-43.0%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$3.7M+13.7%
Total debt$898.0K+551%
Total equity$74.1M+156%
Total assets$78.1M+153%

Cash flow

See full
Operating cash flow-$5.1M-75.8%
CapEx$108.0K+731%
Free cash flow-$5.2M-78.8%

Valuation

See full
Market cap$128.28M+36.1%
Enterprise value$125.53M+39.0%
P/S674.3×

Profitability

See full
Operating margin25,292.9%
Net margin-3,669.9%
FCF margin-852.8%

Returns & leverage

See full
Return on equity-27.6%-10.2pp
Debt / equity0.0×
Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Microbot Medical's net income?
Microbot Medical (MBOT) reported net income of -$3.67M in Q1 2026.
How has Microbot Medical's net income changed year-over-year?
Microbot Medical's net income decreased by 41.1% year-over-year, from -$2.6M to -$3.67M.
What is the long-term trend for Microbot Medical's net income?
Over 4 years (2021 to 2025), Microbot Medical's net income has grown at a 3.8% compound annual growth rate (CAGR), from -$11.31M to -$13.14M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.